ALD

Health eCareers Acquires Arthur L. Davis Publishing (ALD)

Monday, October 25, 2021 - 4:00pm

DENVER, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Health eCareers has acquired Arthur L. Davis Publishing (ALD).

Key Points: 
  • DENVER, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Health eCareers has acquired Arthur L. Davis Publishing (ALD).
  • The acquisition of ALD will further Health eCareers' mission of connecting healthcare professionals with the best career opportunities and resources-from physicians and surgeons to advanced practice providers to nurses.
  • About Health eCareers: Health eCareers brings together physicians, surgeons, nurses, nurse practitioners, PAs, and CRNAs with jobs in every medical specialty.
  • Arthur L. Davis Publishing Agency (ALD) was founded in 1983 in Cedar Falls, Iowa by Arthur L. Davis with the Iowa Board of Nursing Newsletter.

Forge Nano's Denver Innovation Campus - One year later

Monday, October 25, 2021 - 1:38pm

DENVER and THORNTON, Colo., Oct. 25, 2021 /PRNewswire/ --Last fall, Forge Nano Inc. announced the completion of its new surface engineering innovation campus in Denver, CO.

Key Points: 
  • DENVER and THORNTON, Colo., Oct. 25, 2021 /PRNewswire/ --Last fall, Forge Nano Inc. announced the completion of its new surface engineering innovation campus in Denver, CO.
  • The Denver campus is an active development lab, performing cutting edge experimentation on a daily basis.
  • Forge Nano also manufactures its innovative line of Atomic Layer Deposition equipment for a wide range of commercial applications on site.
  • More information about Forge Nano's Atomic Layer Deposition Platform and Products are available at: http://www.forgenano.com
    Based in Denver, CO., Forge Nano is a global leader in surface engineering and precision nano-coating technology, using Atomic Layer Deposition.

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021

Wednesday, October 20, 2021 - 4:45pm

During the third quarter, we continued to make significant progress and accomplished a number of important clinical and corporate objectives.

Key Points: 
  • During the third quarter, we continued to make significant progress and accomplished a number of important clinical and corporate objectives.
  • We are extremely proud to have brought TWYMEEG to patients in Japan through our fruitful partnership with Sumitomo Dainippon Pharma.
  • Third Quarter and Nine Months Ended September 30, 2021 Cash and Revenue
    As of September 30, 2021, cash and cash equivalents were EUR 37.2 million (USD 43.2 million), as compared to EUR 40.2 million (USD 49.4 million) at December 31, 2020.
  • In July 2021, Poxel received a EUR 13.2 million2 milestone payment from its partner Sumitomo Dainippon Pharma for the Imeglimin approval obtained on June 23, 2021.

Forge Nano and Partners Issued in Two ACS Catalysis Publications

Wednesday, October 20, 2021 - 1:38pm

DENVERand THORNTON, Colo., Oct. 20, 2021 /PRNewswire/ --Forge Nano Inc. was featured in two ACS Catalysis publication in the last year demonstrating the benefits of Atomic Layer Deposition technology for chemical manufacturing.

Key Points: 
  • DENVERand THORNTON, Colo., Oct. 20, 2021 /PRNewswire/ --Forge Nano Inc. was featured in two ACS Catalysis publication in the last year demonstrating the benefits of Atomic Layer Deposition technology for chemical manufacturing.
  • The publications are the most recent of many that demonstrate the real-world application of Atomic Layer Deposition for commodity chemical feedstocks and valuable bioderived alternatives.
  • Forge Nano's coating technology improves lifetime, selectivity, durability and can lower operating temperatures, and even decrease operating costs for chemical manufacturing.
  • Forge Nano technology significantly improves materials performance in lithium battery, catalysis, additive manufacturing, pharmaceuticals, and compound semiconductor markets.

SwanBio Therapeutics Announces New Preclinical Data Demonstrating Proof of Principle for SBT101 Gene therapy as a Potential Treatment of Adrenomyeloneuropathy

Tuesday, October 19, 2021 - 11:00am

SwanBio Therapeutics, a gene therapy company focused on developing treatments for patients with genetically defined neurological conditions, today announced new preclinical efficacy and safety data supporting the potential of the companys lead program, SBT101, as a disease-modifying treatment for adrenomyeloneuropathy (AMN).

Key Points: 
  • SwanBio Therapeutics, a gene therapy company focused on developing treatments for patients with genetically defined neurological conditions, today announced new preclinical efficacy and safety data supporting the potential of the companys lead program, SBT101, as a disease-modifying treatment for adrenomyeloneuropathy (AMN).
  • SBT101, a novel AAV-based gene therapy, is designed to compensate for the disease-causing ABCD1 mutation, increasing ABCD1 expression and reducing VLCFA levels.
  • Taken together, these findings support the continued evaluation of SBT101 as a potential disease-modifying treatment for AMN as we advance towards the clinic.
  • SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions.

Forge Nano sells Prometheus™ Powder ALD Equipment to Mitsui Kinzoku, Japan

Thursday, October 14, 2021 - 1:39pm

DENVER, Oct. 14, 2021 /PRNewswire/ -- Forge Nano, a Denver-based advanced materials equipment company, has sold Mitsui Mining & Smelting Co., Ltd. ("Mitsui Kinzoku") one of their flagship Prometheus powder ALD (PALD) systems.

Key Points: 
  • DENVER, Oct. 14, 2021 /PRNewswire/ -- Forge Nano, a Denver-based advanced materials equipment company, has sold Mitsui Mining & Smelting Co., Ltd. ("Mitsui Kinzoku") one of their flagship Prometheus powder ALD (PALD) systems.
  • Mitsui Kinzoku, an investor in Forge Nano, is using the Prometheus system to perform various proofs-of-concept and plans to use Forge Nano's commercial scale equipment for mass production.
  • With advanced powder fluidization aids and up to 8 ALD chemical precursor lines, Prometheus is the most capable powder ALD system on the market.
  • Forge Nano's team of ALD experts guide our customers through the entire process, making ALD feasible for nearly any industry.

Forge Nano Installs Prometheus™ Powder Atomic Layer Deposition (PALD) equipment at Air Liquide's Tokyo Innovation Campus

Friday, October 1, 2021 - 1:32pm

DENVER and YOKOSUKA, Japan, Oct. 1, 2021 /PRNewswire/ -- Forge Nano, a Denver-based advanced materials equipment company, has installed one of their flagship Prometheus powder ALD (PALD) systems at Air Liquide Japan Ltd.'s Tokyo Innovation Campus.

Key Points: 
  • DENVER and YOKOSUKA, Japan, Oct. 1, 2021 /PRNewswire/ -- Forge Nano, a Denver-based advanced materials equipment company, has installed one of their flagship Prometheus powder ALD (PALD) systems at Air Liquide Japan Ltd.'s Tokyo Innovation Campus.
  • Air Liquide, an investor in Forge Nano, is using the Prometheus system to perform various proofs-of-concept for subsequent scale-up at customer facilities using Forge Nano's commercial scale equipment.
  • "Forge Nano values Air Liquide as a key strategic investor and partner in various established markets.
  • Based in Denver, CO., Forge Nano is a global leader in surface engineering and precision nano-coating technology, using Atomic Layer Deposition.

Poxel Announces its Participation at Investor Conferences in October 2021

Thursday, September 30, 2021 - 7:30am

POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor conferences in October 2021.

Key Points: 
  • POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor conferences in October 2021.
  • HealthTech Innovation Days Conference France Biotech - Paris, France (virtual)
    Thomas Kuhn, CEO of Poxel, and Anne Renevot, CFO, will be available for one-on-one virtual meetings.
  • Members of the Poxel management team will present Poxels two NASH clinical-stage candidates, PXL770 and PXL065, and will be available for one-on-one virtual meetings.
  • Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders.

Global $761.1 Mn High-k And CVD ALD Metal Precursors (Interconnect, Capacitors, Gates) Markets to 2028 - ResearchAndMarkets.com

Wednesday, September 29, 2021 - 10:07am

The "Global High-k And CVD ALD Metal Precursors Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global High-k And CVD ALD Metal Precursors Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global high-k and CVD ALD metal precursors market size is projected to reach USD 761.1 million by 2028, registering a CAGR of 6.2% from 2021 to 2028.
  • The trend of miniaturization of semiconductor and electronic devices and the need for enhancing their performance is expected to drive the market growth.
  • Atomic Layer Deposition (ALD) is the subclass of the Chemical Vapor Deposition (CVD) process, which is used to manufacture thin films.

Poxel Announces its Participation at Upcoming Scientific Conferences Related to Adrenoleukodystrophy (ALD)

Monday, September 27, 2021 - 7:30am

POXEL SA (Euronext POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Poxel team will participate at several upcoming scientific conferences related to X-linked adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease with no approved therapies.

Key Points: 
  • POXEL SA (Euronext POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Poxel team will participate at several upcoming scientific conferences related to X-linked adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease with no approved therapies.
  • Poxel's scientific team will present data and plans pertaining to ALD that align with the recently announced new strategic direction of increasing Poxels focus on rare metabolic diseases.
  • Poxel is committed to focus its pipeline on high value, rare metabolic indications and NASH, with the goal of creating pipeline synergies, maximizing resources, and driving shareholder value.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.